Kelyniam Global Acquires MED-ALLY

CANTON, Conn.--(BUSINESS WIRE)--

Kelyniam Global, Inc. (OTC Pink: KLYG), an innovative medical device design and manufacturing company, announced today it has acquired MED-ALLY, LLC as part of its product diversification initiative. MED-ALLY applies custom, proprietary Neuromodulation technology to create a number of external and implantable medical devices that can be used to treat a wide array of conditions including chronic pain management, urinary incontinence, sleep apnea, Tinnitus and Deep Brain Stimulation applications such as Alzheimer's, Epilepsy, and Parkinson's disease.

Kelyniam's current product line is made up of precise and novel, customized PEEK cranial and facial implants used to fill bony voids caused by trauma, birth defects or disease. Its streamlined CAD/CAM design and manufacturing techniques enable Kelyniam to deliver patient-specific PEEK implants to surgeons in as little as 24 hours from the receipt of an order – a timeframe which is unmatched in its industry. The ability to provide custom PEEK implants quickly and accurately can reduce the time between trauma and implantation and provides surgeons additional treatment options.

“Kelyniam's mission is to develop and manufacture medical devices that significantly improve medical care, surgical outcomes and patient quality of life, and our acquisition of MED-ALLY greatly enhances our ability to do just that,” said Tennyson Anthony, president and CEO of Kelyniam Global. “Our cost-effective Implantable Pulse Generators will provide an alternative to addictive opiates for patients suffering from chronic pain, and provide new hope and the promise of an enhanced quality of life for many patients suffering from other ailments who currently have no viable alternative treatment.”

MED-ALLY founders, John Mulvihill and Raja Hitti, bring more than 50 years of combined medical device design, development, manufacturing, sales and marketing experience that will have a positive impact on Kelyniam customers globally. MED-ALLY has agreements with multiple early-stage neuromodulation companies to deliver an active implantable medical device system to treat new therapeutic indications not currently available in the market. A recent market study from Neurotech Reports estimates the neuromodulation medical device market to be $4 billion and growing more than 18% annually.

For more go to www.kelyniam.com.

About Kelyniam Global, Incorporated

Kelyniam Global (OTC Pink: KLYG) is an innovative Medical Device Manufacturing Company specializing in the production of custom PEEK cranial and facial prosthetics and proprietary, implantable neuromodulation medical device systems. Its Engineering Division works diligently with medical professionals - allowing them to operate more effectively, improve patient care and surgical outcomes while reducing health care cost.

Forward-Looking Statements

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate," "believes," "estimate," "expect," "should," "intend," "projects," "objective" and "appears" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.